Seer (SEER) Net Income towards Common Stockholders (2020 - 2026)
Seer (SEER) recorded quarterly Net Income towards Common Stockholders of -$16.8 million in Q1 2026, down 5.27% quarter-over-quarter from -$16.0 million in Q4 2025, and up 15.6% on a YoY basis from -$14.6 million in Q1 2025.
Seer (SEER) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Seer's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$16.8 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 15.6% year-over-year to -$16.8 million; the TTM figure through Mar 2026 stood at -$70.5 million (up 18.15% YoY), while the FY2025 annual figure was -$73.6 million, up 15.25% from the prior year.
- Net Income towards Common Stockholders was -$16.8 million for Q1 2026 at Seer, down from -$16.0 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $67.5 million in Q4 2023 to a low of -$24.0 million in Q3 2022.
- Historically, Net Income towards Common Stockholders has averaged -$16.0 million across 5 years, with a median of -$21.3 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders soared 399.87% in 2023, then tumbled 132.56% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$22.5 million in 2022, then jumped by 399.87% to $67.5 million in 2023, then slumped by 132.56% to -$22.0 million in 2024, then climbed by 27.27% to -$16.0 million in 2025, then dropped by 5.27% to -$16.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$16.8 million (Q1 2026), -$16.0 million (Q4 2025), and -$18.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Seer | 99.67 Mn | 99.67 Mn | 982,000.00 | -16.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.84 Mn |
| Dec 31, 2025 | -15.99 Mn |
| Sep 30, 2025 | -18.23 Mn |
| Jun 30, 2025 | -19.42 Mn |
| Mar 31, 2025 | -19.95 Mn |
| Dec 31, 2024 | -21.99 Mn |
| Sep 30, 2024 | -21.33 Mn |
| Jun 30, 2024 | -22.85 Mn |
| Mar 31, 2024 | -20.68 Mn |
| Dec 31, 2023 | 67.55 Mn |
| Sep 30, 2023 | -21.09 Mn |
| Jun 30, 2023 | -23.43 Mn |
| Mar 31, 2023 | -23.96 Mn |
| Dec 31, 2022 | -22.53 Mn |
| Sep 30, 2022 | -23.98 Mn |
| Jun 30, 2022 | -22.82 Mn |
| Mar 31, 2022 | -23.65 Mn |
| Dec 31, 2021 | -19.74 Mn |
| Sep 30, 2021 | -18.39 Mn |
| Jun 30, 2021 | -16.62 Mn |